Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Menopause | D008593 | EFO_0003922 | N95 | 5 | 4 | 4 | 7 | 2 | 22 |
Postmenopause | D017698 | — | — | 5 | 5 | 3 | 2 | 3 | 18 |
Atrophy | D001284 | — | — | 2 | — | 5 | 1 | 2 | 10 |
Atrophic vaginitis | D059268 | EFO_1001271 | — | 2 | — | 3 | 3 | 1 | 9 |
Hot flashes | D019584 | — | — | — | — | 4 | 2 | 2 | 8 |
Vaginitis | D014627 | EFO_0005757 | N76 | 3 | — | 1 | 3 | 1 | 8 |
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 4 | 1 | 5 |
Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | 1 | 4 | — | 5 |
Prolapse | D011391 | — | — | — | — | 1 | 4 | — | 5 |
Coronary disease | D003327 | — | — | — | 1 | 4 | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 8 | 2 | — | 4 | 16 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | 6 | — | 2 | 8 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 5 | — | — | 6 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 3 | — | — | 4 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 4 | — | — | 4 |
Coronary artery disease | D003324 | — | I25.1 | — | 1 | 3 | — | — | 3 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | 1 | — | — | 2 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | 1 | — | — | 2 |
Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | — | — | 2 |
Anorexia | D000855 | — | R63.0 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Triple negative breast neoplasms | D064726 | — | — | 1 | 3 | — | — | — | 3 |
Male breast neoplasms | D018567 | — | — | — | 2 | — | — | 1 | 3 |
Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | — | 2 |
Risk reduction behavior | D040242 | — | — | — | 1 | — | — | — | 1 |
Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Carcinoma in situ | D002278 | — | D09.9 | — | 1 | — | — | — | 1 |
Breast carcinoma in situ | D000071960 | — | D05 | — | 1 | — | — | — | 1 |
Ductal carcinoma breast | D018270 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | — | — | — | 1 | 2 |
Estrogen replacement therapy | D015914 | — | — | 2 | — | — | — | — | 2 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | — | 1 |
Sleep | D012890 | GO_0030431 | — | 1 | — | — | — | — | 1 |
Metrorrhagia | D008796 | — | N92.1 | 1 | — | — | — | — | 1 |
Premature menopause | D008594 | — | E28.31 | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
Gender dysphoria | D000068116 | — | F64 | — | — | — | — | 1 | 1 |
Breast density | D000071060 | — | — | — | — | — | — | 1 | 1 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 1 | 1 |
Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | — | — | — | 1 | 1 |
Drug common name | Estrogens conjugated |
INN | — |
Description | Conjugated estrogens (CEs), or conjugated equine estrogens (CEEs), sold under the brand name Premarin among others, is an estrogen medication which is used in menopausal hormone therapy and for various other indications. It is a mixture of the sodium salts of estrogen conjugates found in horses, such as estrone sulfate and equilin sulfate. CEEs are available in the form of both natural preparations manufactured from the urine of pregnant mares and fully synthetic replications of the natural preparations. They are formulated both alone and in combination with progestins such as medroxyprogesterone acetate. CEEs are usually taken by mouth, but can also be given by application to the skin or vagina as a cream or by injection into a blood vessel or muscle.
|
Classification | Unknown |
Drug class | estrogens |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 12126-59-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1201649 |
ChEBI ID | — |
PubChem CID | 656613 |
DrugBank | DB00286 |
UNII ID | — |